GLPBio

FGFR

FGFRs (fibroblast growth factor receptors) are transmembrane tyrosine kinase receptor. It is involved in carcinogenesis and plays an important role in cell differentiation, survival and proliferation etc.

Products Related to FGFR(109)

  • GC13547 structure
    GC13547Dovitinib (TKI-258, CHIR-258)
    CAS: 405169-16-6
    Purity: >98.00%

    Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity.

  • GC17283 structure
    GC17283AP26113
    CAS: 1197958-12-5
    Purity: >99.50%

    AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.

  • GC10055 structure
    GC10055BGJ398 (Infigratinib)
    CAS: 872511-34-7
    Purity: >99.50%

    BGJ398 (Infigratinib) is an oral, ATP-competitive pan-FGFR tyrosine kinase inhibitor (FGFR1: IC 50 = 0.9nM; FGFR2: IC 50 = 1.4nM; FGFR3: IC 50 = 1nM; FGFR4: IC 50 = 60nM).

  • GC10491 structure
    GC10491SSR128129E
    CAS: 848318-25-2
    Purity: >99.50%

    allosteric inhibitor of FGFR1, orally-active

  • GC10759 structure
    GC10759CH5183284 (Debio-1347)
    CAS: 1265229-25-1
    Purity: >99.00%

    CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

  • GC10833 structure
    GC10833BLU9931
    CAS: 1538604-68-0
    Purity: >99.50%

    FGFR4 inhibitor,potent and irreversible

  • GC11622 structure
    GC11622TG 100801
    CAS: 867331-82-6
    Purity: >98.00%
  • GC11705 structure
    GC11705Nintedanib (BIBF 1120)
    CAS: 656247-17-5
    Purity: >99.50%

    Nintedanib (BIBF 1120) is an orally available triple tyrosine kinase inhibitor that can inhibit vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3, fibroblast growth factor receptor (FGFR) -1, -2, and -3, as well as platelet-derived growth factor receptor (PDGFR) α and β tyrosine kinases with an IC 50 value of 4.16±0.04μM, 5.62±2.64μM, and 6.32±1.18μM for HNE-1, CNE-2, and HONE-1, respectively.

  • GC12049 structure
    GC12049PD 161570
    CAS: 192705-80-9
    Purity: >99.00%

    FGFR inhibitor

  • GC12145 structure
    GC12145ENMD-2076 L-(+)-Tartaric acid
    CAS: 1291074-87-7
    Purity: >98.50%
  • GC12149 structure
    GC12149E-3810
    CAS: 1058137-23-7
    Purity: >98.50%
  • GC12730 structure
    GC12730Pazopanib Hydrochloride
    CAS: 635702-64-6
    Purity: >99.50%

    VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor

  • GC12776 structure
    GC12776SKLB610
    CAS: 1125780-41-7
    Purity: >98%

    An inhibitor of VEGFR2

  • GC13410 structure
    GC13410Masitinib (AB1010)
    CAS: 790299-79-5
    Purity: >99.50%

    Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.

  • GC13424 structure
    GC13424LY2874455
    CAS: 1254473-64-7
    Purity: >98.00%

    A pan-FGFR inhibitor

  • GC13848 structure
    GC13848LY2784544
    CAS: 1229236-86-5
    Purity: >99.50%

    Potent inhibitor of JAK2

  • GC14005 structure
    GC14005AZD4547
    CAS: 1035270-39-3
    Purity: >99.50%

    FGFR inhibitor

  • GC14396 structure
    GC14396Ponatinib (AP24534)
    CAS: 943319-70-8
    Purity: >99.00%

    Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

  • GC14592 structure
    GC14592KW 2449
    CAS: 1000669-72-6
    Purity: >99.50%

    A multi-kinase inhibitor

  • GC14660 structure
    GC14660SU 5402
    CAS: 215543-92-3
    Purity: >98.00%

    SU 5402 is a multi-targeted receptor tyrosine kinase inhibitor that inhibit against vascular endothelial growth factor receptor 2 (VEGF-R2) and fibroblast growth factor receptor 1 (FGF-R1) tyrosine kinase activity with IC 50 values of 20 and 30nM, respectively.

  • GC15217 structure
    GC15217Danusertib (PHA-739358)
    CAS: 827318-97-8
    Purity: >98.50%

    A pan-Aurora kinase and Abl inhibitor

  • GC15454 structure
    GC15454Lenvatinib (E7080)
    CAS: 417716-92-8
    Purity: >99.50%

    E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.

  • GC15801 structure
    GC15801ACTB-1003
    CAS: 939805-30-8
    Purity: >98.00%

    ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.

  • GC16028 structure
    GC16028NVP-BGJ398 phosphate
    CAS: 1310746-10-1
    Purity: >98%